LDXHF (Lumos Diagnostics Holdings) Research & Development: $0.27 Mil (TTM As of Dec. 2025)


LDXHF Lumos Diagnostics Holdings Ltd LDXHF
31 GF Score
Price $0.08
GF Value $0.02
Valuation Significantly Overvalued
! 7 Warning Signs
View Full Analysis

What is Lumos Diagnostics Holdings Research & Development?

Lumos Diagnostics Holdings LDXHF 31 Research & Development is $0.27 Mil as of Dec. 2025. GuruFocus rates LDXHF with a GF Score™ of 31/100 and a GF Value™ of $0.02 (Significantly Overvalued). The stock has 7 warning signs investors should review.

Research & Development is the aggregate amount of research and development expenses during the year. Lumos Diagnostics Holdings's Research & Development for the six months ended in Dec. 2025 was $0.23 Mil. Its Research & Development for the trailing twelve months (TTM) ended in Dec. 2025 was $0.27 Mil.

Lumos Diagnostics Holdings  (OTCPK:LDXHF) Research & Development Explanation

If competitive advantage is created by a patent or tech advantage, at some point it will disappear.

High R&D usually dictates high SG&A which threatens the competitive advantage.

Lumos Diagnostics Holdings Research & Development Related Terms

Lumos Diagnostics Holdings Research & Development Historical Data

* Premium members only.

The historical data trend for Lumos Diagnostics Holdings's Research & Development can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Lumos Diagnostics Holdings Research & Development Chart

Lumos Diagnostics Holdings Annual Data
Trend Jun22 Jun23 Jun24 Jun25
Research & Development
1.33 0.42 0.07 0.11

Lumos Diagnostics Holdings Semi-Annual Data
Dec20 Dec21 Jun22 Dec22 Jun23 Dec23 Jun24 Dec24 Jun25 Dec25
Research & Development Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.11 -0.04 0.07 0.04 0.23
LDXHF
31GF Score
Lumos Diagnostics Holdings Ltd LDXHF
Research & Development is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Lumos Diagnostics Holdings Research & Development Calculation

This is the expense the company spent on research and development.

Research & Development for the trailing twelve months (TTM) ended in Dec. 2025 adds up the semi-annually data reported by the company within the most recent 12 months, which was $0.27 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about Research & Development →
What does a Research & Development of $0.27 Mil mean?
Lumos Diagnostics Holdings (LDXHF) has a Research & Development of $0.27 Mil as of Dec. 2025. Research and development expense is the total cost for research and development activities. View historical data on Lumos Diagnostics Holdings and its competitors.
Is Lumos Diagnostics Holdings' Research & Development too high?
Lumos Diagnostics Holdings' current Research & Development is $0.27 Mil. Overall, Lumos Diagnostics Holdings has a GF Score™ of 31/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Lumos Diagnostics Holdings' Research & Development compare to ABT and SYK?
Lumos Diagnostics Holdings' Research & Development of $0.27 Mil can be compared against companies in the Medical Devices & Instruments industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Research & Development for a Medical Devices & Instruments company?
A good Research & Development depends on the Medical Devices & Instruments industry context. However, Research & Development should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Research & Development mean?
A high Research & Development can signal that a stock is expensive relative to its fundamentals. Research and development expense is the total cost for research and development activities. View historical data on Lumos Diagnostics Holdings and its competitors. Lumos Diagnostics Holdings's current Research & Development is $0.27 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Lumos Diagnostics Holdings stock overvalued right now?
Based on GuruFocus' analysis, Lumos Diagnostics Holdings (LDXHF) is currently considered Significantly Overvalued. The stock's GF Value™ is $0.02, compared to a current price of $0.08 — trading 300% above its estimated fair value. The current Research & Development is $0.27 Mil. Lumos Diagnostics Holdings' overall GF Score™ is 31/100 with 7 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Research & Development calculated?
Research & Development is calculated from a company's financial statements. For Lumos Diagnostics Holdings (LDXHF), the current Research & Development is $0.27 Mil as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Lumos Diagnostics Holdings (LDXHF) Overvalued in 2026?

Based on GuruFocus' analysis, Lumos Diagnostics Holdings stock appears to be overvalued. The current stock price of $0.08 is trading 300% above its estimated GF Value™ of $0.02. GuruFocus considers Lumos Diagnostics Holdings to be Significantly Overvalued.

Key valuation signals for LDXHF:

  • Research & Development: $0.27 Mil
  • GF Value™: $0.02 vs. price of $0.08 (300% above fair value)
  • GF Score™: 31/100 with 7 warning signs

No single metric tells the full story. See the LDXHF stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Lumos Diagnostics Holdings Business Description

Other Exchanges LDX:Australia
Address 2724 Loker Avenue West, Carlsbad, CA, USA, 92010
Lumos Diagnostics Holdings Ltd is engaged in the development, manufacture, and distribution of point-of-care diagnostic (POC) tests and associated readers for analysis of POC diagnostic tests. The group is dedicated to providing contract research and development services, focusing on the innovation, development, manufacturing, and commercialization of point-of-care diagnostic solutions for both clinical and consumer applications. It generates maximum revenue from commercial services and solutions relating to POC diagnostic tests. The group has one operating segment, which is the provision of point-of-care diagnostics goods and services. The Company operates in two geographical regions, the United States and Australia and the majority of revenue is generated from the United States.
31GF Score

Get the complete analysis for LDXHF

Research & Development is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$0.08
Price
$0.02
GF Value